La vendita allo scoperto per Talis Biomedical dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Talis Biomedical. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Talis Biomedical (OTC:TLIS) Azioni, Report sulle vendite allo scoperto

Talis Biomedical

Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.

TALIS BIOMEDICAL CORP by Talis Biomedical Corporation

Talis Biomedical Corp

Roth MKM analyst George Kelly reiterates Topgolf Callaway Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODG#NYSE">MODG</a>) with a Buy and lowers the price target from $17 to $16.

News

Price Target

Reiteration

Analyst Ratings

MODG

Roth MKM Reiterates Buy on Topgolf Callaway Brands, Lowers Price Target to $16

WIIM

WYNN

Wynn Resorts shares are trading higher after Tilman Fertitta disclosed a 9.9% passive stake in the company.

RBC Capital analyst Sabahat Khan reiterates AutoCanada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACQ#TSX">ACQ</a>) with a Sector Perform and maintains C$18 price target.

TSX:ACQ

RBC Capital Reiterates Sector Perform on AutoCanada, Maintains C$18 Price Target

Deep-pocketed investors have adopted a bearish approach towards Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DJT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 19 extraordinary options activities for Trump Media &amp; Technology. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 42% leaning bullish and 47% bearish. Among these notable options, 10 are puts, totaling $744,800, and 9 are calls, amounting to $5,671,118.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $60.0 for Trump Media &amp; Technology, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Trump Media &amp; Technology's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Trump Media &amp; Technology's significant trades, within a strike price range of $20.0 to $60.0, over the past month.
<h3>Trump Media &amp; Technology Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731599132_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DJT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.6</td>
<td>$8.05</td>
<td>$8.55</td>
<td>$23.00</td>
<td>$4.2M</td>
<td>401</td>
<td>5.0K</td>
</tr>
<tr>
<td>DJT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$9.05</td>
<td>$8.65</td>
<td>$8.65</td>
<td>$21.00</td>
<td>$653.0K</td>
<td>406</td>
<td>755</td>
</tr>
<tr>
<td>DJT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$7.25</td>
<td>$6.85</td>
<td>$6.93</td>
<td>$24.00</td>
<td>$523.2K</td>
<td>150</td>
<td>755</td>
</tr>
<tr>
<td>DJT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$6.15</td>
<td>$5.95</td>
<td>$6.15</td>
<td>$33.00</td>
<td>$305.1K</td>
<td>1.3K</td>
<td>595</td>
</tr>
<tr>
<td>DJT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.7</td>
<td>$2.62</td>
<td>$2.7</td>
<td>$30.00</td>
<td>$108.0K</td>
<td>12.1K</td>
<td>863</td>
</tr>
</tbody>
</table>

<h3>About Trump Media &amp; Technology</h3>
Trump Media &amp; Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest global conversation without discriminating against political ideology.
Having examined the options trading patterns of Trump Media &amp; Technology, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Trump Media &amp; Technology</h3>
<ul>
<li>With a trading volume of 9,305,086, the price of DJT is down by -6.51%, reaching $27.05.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 81 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Trump Media &amp; Technology with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

This Is What Whales Are Betting On Trump Media & Technology

Benzinga's options scanner just detected over 11 options trades for Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) summing a total amount of $882,973.
At the same time, our algo caught 6 for a total amount of 285,343.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $25.0 for Carnival, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Carnival's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Carnival's whale activity within a strike price range from $20.0 to $25.0 in the last 30 days. 
<h3>Carnival Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731599128_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.3</td>
<td>$6.1</td>
<td>$6.15</td>
<td>$20.00</td>
<td>$468.6K</td>
<td>11.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$6.5</td>
<td>$6.45</td>
<td>$6.45</td>
<td>$22.00</td>
<td>$301.2K</td>
<td>1.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$6.6</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$22.00</td>
<td>$130.0K</td>
<td>1.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.15</td>
<td>$5.0</td>
<td>$5.15</td>
<td>$20.00</td>
<td>$103.0K</td>
<td>37.0K</td>
<td>204</td>
</tr>
<tr>
<td>CCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.73</td>
<td>$1.72</td>
<td>$1.72</td>
<td>$25.00</td>
<td>$89.4K</td>
<td>751</td>
<td>520</td>
</tr>
</tbody>
</table>

<h3>About Carnival</h3>
Carnival is the largest global cruise company, with 92 ships in service at the end of fiscal 2023. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&amp;O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It's currently folding its P&amp;O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted nearly 13 million guests in 2019, prior to covid-19, a level it reached again in 2023.
<h3>Carnival's Current Market Status</h3>
<ul>
<li>Trading volume stands at 3,772,389, with CCL's price up by 1.02%, positioned at $24.8.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 35 days.</li>
</ul>
<h3>Expert Opinions on Carnival</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $28.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on Carnival, maintaining a target price of $28. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Carnival options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

What the Options Market Tells Us About Carnival

Investors with a lot of money to spend have taken a bearish stance on Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 33 uncommon options trades for Boeing.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 48%, bearish.
Out of all of the special options we uncovered, 15 are puts, for a total amount of $1,271,013, and 18 are calls, for a total amount of $1,109,177.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $120.0 to $200.0 for Boeing over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Boeing's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Boeing's substantial trades, within a strike price spectrum from $120.0 to $200.0 over the preceding 30 days.
<h3>Boeing 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731599122_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$46.0</td>
<td>$43.7</td>
<td>$45.19</td>
<td>$185.00</td>
<td>$451.9K</td>
<td>832</td>
<td align="right">100</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$15.0</td>
<td>$14.9</td>
<td>$15.0</td>
<td>$145.00</td>
<td>$109.5K</td>
<td>509</td>
<td align="right">101</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$15.4</td>
<td>$15.05</td>
<td>$15.25</td>
<td>$155.00</td>
<td>$108.3K</td>
<td>3.6K</td>
<td align="right">147</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$5.0</td>
<td>$4.2</td>
<td>$5.0</td>
<td>$145.00</td>
<td>$100.0K</td>
<td>22.0K</td>
<td align="right">201</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.05</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$145.00</td>
<td>$91.5K</td>
<td>2.8K</td>
<td align="right">961</td>
</tr>
</tbody>
</table>

<h3>About Boeing</h3>
Boeing is a major aerospace and defense firm. It operates in three segments: commercial airplanes; defense, space, and security; and Global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with Lockheed, Northrop, and several other firms to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.
<h3>Boeing's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 2,638,119, the BA's price is up by 0.61%, now at $140.83. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 76 days.</li>
</ul>
<h3>Expert Opinions on Boeing</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $148.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Boeing with a target price of $200. 
&#x2A; In a cautious move, an analyst from Bernstein downgraded its rating to Market Perform, setting a price target of $169. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Underweight rating on Boeing, which currently sits at a price target of $85. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Underweight rating on Boeing, which currently sits at a price target of $86. 
&#x2A; Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for Boeing, targeting a price of $200. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Boeing options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

This Is What Whales Are Betting On Boeing

According to the <a href="https://www.benzinga.com/real-estate/24/11/41710617/the-fed-cut-rates-so-why-are-mortgage-rates-climbing-the-truth-behind-the-housing-markets-latest-cur">Mortgage </a>Bankers Association (MBA), mortgage demand took a sharp dive, with applications plummeting 11% as interest rates hovered above 7%. The MBA's Chief Economist, Mike Fratantoni, remarked that affordability is being squeezed tightly and first-time buyers, particularly, are feeling the heat.&nbsp;
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
<li>‘Beating the market through ethical real estate investing' —<a href="https://www.benzinga.com/money/invest-with-roots"> this platform aims to give tenants equity in the homes they live in while scoring 17.38% average annual returns for investors – here&#8217;s how to join with just $100</a></li>
</ul>
"Homebuyers, particularly first-time buyers who do not have the ability to make larger down payments, have been more willing to accept a higher payment burden," Fratantoni commented. The average 30-year fixed-rate mortgage peaked in May at 7.2%, keeping some potential buyers on the sidelines and leaving those dependent on financing in a pinch.
The squeeze on buyers reflects the sixth week of declining mortgage applications, showing just how much the current rate environment has cooled off what was previously a red-hot market. Joel Kan, an economist with the MBA, noted, "Purchase activity has fallen to its lowest level since mid-August and refinance activity has hit its lowest since May."&nbsp;
Trending: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a>
 He explained that refinancing is particularly rate-sensitive; as a result, refinance applications dropped 19% in just one week, though they remain 48% higher than the same week last year.
"Most people refinancing are looking for immediate relief, but even those with larger loans are opting out now," Kan noted.
"They're susceptible to even slight changes in rates." He pointed out that the average refinance loan size has dropped below $300,000, signaling that borrowers with larger debts may hesitate to lock in rates at this level.&nbsp;
The impact doesn't stop with refinance applicants. Mortgage applications for home purchases also slid, dipping 5% for the week and barely registering a 2% increase from last year.&nbsp;
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
According to Kan, home-buying activity has seen a boost over recent months as more inventory becomes available and prices ease a bit, but the recent rate hikes seem to be pricing some buyers right back out. "People are simply less willing to leap into a new mortgage with such high rates. The<a href="https://www.benzinga.com/personal-finance/24/11/41728751/even-as-inflation-cools-most-americans-cant-get-ahead-and-continue-living-paycheck-to-paycheck-r"> higher costs</a> are turning what would have been a manageable purchase into a hard sell," he observed.
Experts are mixed on where rates might head in the near term, but there's some cautious optimism for 2024. Analysts at S&amp;P Global Ratings expect mortgage rates to gradually ease and if that pans out, the housing market may find some breathing room.&nbsp;
Read Next:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
</ul>

Real Estate

With Interest Rates Soaring, Weekly Mortgage Demand Nosedives 11% – A Warning Sign For The Real Estate Market?

Roth MKM analyst George Kelly reiterates Beachbody Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) with a Buy and maintains $12 price target.

The Beachbody Company, Inc. Class A Common Stock

BODI

Roth MKM Reiterates Buy on Beachbody Co, Maintains $12 Price Target

Shares of Cisco Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) declined in early trading on Thursday, even after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41955614/cisco-q1-earnings-revenue-beat-eps-beat-strong-start-to-year-customers-investing-in-ai-and-more">upbeat fiscal first-quarter earnings</a>.
The company reported its results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
<ul>
<li>Goldman Sachs <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5a1c4e20efacff00015a984c/michael-ng">analyst Michael Ng</a> maintained a Neutral, while raising the price target higher from $51 to $56.</li>
<li>Piper Sandler <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5a09e167efacff00012b1912/james-fish">analyst James Fish</a> reiterated a Neutral, while lifting the price target from $52 to $57.</li>
<li>Morgan Stanley <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2143eaaa0001698f54/meta-marshall">analyst Meta Marshall</a> reaffirmed an Overweight rating, while raising the price target from $58 to $62.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Goldman Sachs: Cisco Systemsreported its fiscal first-quarter earnings at 91 cents per share, higher than consensus of 87 cents per share, with the beat being driven by better-than-expected gross margins and in-line revenue of $13.8 billion, Ng said in a note. Order growth ex-Splunk accelerated to 9% year-on-year, with 17% growth in Enterprise and 22% in Service Provider &amp; Cloud, he added.
"Webscale, which is a subset within Service Provider &amp; Cloud, was a bright spot with orders growing triple digits," including more than $300 million of AI orders, the analyst wrote. The AI momentum puts Cisco Systems "well on track" to exceed its fiscal 2025 target of $1 billion in AI orders, he further stated.
Piper Sandler: Cisco Systems posted total revenues of $13.84 billion, which represents a 6% year-on-year decline but came in higher than expectations by around 1%, Fish said. "The upside again came via Product, though primarily was due to ~ $20M higher Splunk contribution," he further wrote.
Management raised their annual revenue guidance by $200 million at the midpoint, "given the demand environment, but more likely the upside of recurring Splunk revenue," the analyst stated. This led Cisco Systems to raise its earnings guidance to $3.60-$3.66 per share, he added.
Morgan Stanley: Cisco Systems reported higher-than-expected quarterly results, largely due to Splunk's outperformance, Marshall said. "Upending on networking is improving coming out of inventory digestion," he added.
The company benefited from "meaningful traction" across three AI investments, the first being more than $300 million in AI orders, the analyst stated. Second was double digit growth in networking orders due to improving connectivity ahead of AI and the third was "in terms of data center modernization for enterprises ahead of AI investments," he further wrote.
Price Action: Shares of Cisco Systems had declined by 1.30% to $58.41 at the time of publication on Thursday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41939200/cisco-earnings-on-deck-as-ai-cybersecurity-drive-growth-potential">Cisco Earnings On Deck As AI, Cybersecurity Drive Growth Potential</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings Beats

Movers

Trading Ideas

CSCO

Cisco Systems Analysts Raise Forecasts On 'Meaningful Traction' Across 3 AI Investments

Roth MKM analyst Bill Kirk maintains Ayr Wellness (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>) with a Buy and lowers the price target from $3.5 to $3.

AYRWF

Roth MKM Maintains Buy on Ayr Wellness, Lowers Price Target to $3

RBC Capital analyst Drew McReynolds maintains Boat Rocker Media (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BRMI#TSX">BRMI</a>) with a Outperform and lowers the price target from C$2.5 to C$1.5.

TSX:BRMI

RBC Capital Maintains Outperform on Boat Rocker Media, Lowers Price Target to C$1.5

RBC Capital analyst James McGarragle maintains CAE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CAE#TSX">CAE</a>) with a Outperform and raises the price target from C$27 to C$34.

TSX:CAE

RBC Capital Maintains Outperform on CAE, Raises Price Target to C$34

Scotiabank analyst Phil Hardie maintains Element Fleet Mgmt (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EFN#TSX">EFN</a>) with a Sector Outperform and lowers the price target from C$33 to C$32.

TSX:EFN

Scotiabank Maintains Sector Outperform on Element Fleet Mgmt, Lowers Price Target to C$32

RBC Capital analyst Pammi Bir maintains Crombie REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CRR#TSX">CRR</a>) with a Sector Perform and raises the price target from C$15 to C$16.

TSX:CRR

TSX:CRR/UN

RBC Capital Maintains Sector Perform on Crombie REIT, Raises Price Target to C$16

Scotiabank analyst Divya Goyal maintains Converge Tech Solns (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CTS#TSX">CTS</a>) with a Sector Perform and lowers the price target from C$5 to C$4.

TSX:CTS

Scotiabank Maintains Sector Perform on Converge Tech Solns, Lowers Price Target to C$4

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares are trading lower in possible response to Amazon.com Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) new upfront pricing for <a href="https://www.benzinga.com/topic/telehealth">telehealth visits and treatment plans</a>. 
What Happened: Amazon announced Thursday that its Amazon One Medical telehealth service is introducing low upfront pricing for clinical visits and treatment plan, as well as free medication delivery for Prime members.
Prime members can now see the total monthly cost or individual use cost for Amazon One Medical Pay-per-visit virtual visits and medications from the Amazon Pharmacy before signing up for care.
"This simple care experience was built to meet the needs of today's customer. At Amazon, we're working to reduce the burden on patients who'd like to move forward with care, but may be tired of navigating the hurdles of our health care system, waiting in a long line at the pharmacy, or worried about a surprise bill or medication cost," said Vin Gupta, chief medical officer for Amazon Pharmacy. 
Prime members who use Amazon Pharmacy will pay a low, upfront price for medications and get those medications delivered for free for a range of common health, beauty and lifestyle concerns including anti-aging skin care treatment, men&#8217;s hair loss, erectile dysfunction and motion sickness.
See Also: <a href="https://www.benzinga.com/general/biotech/24/11/41964382/amazons-secret-fertility-tracker-project-launched-under-jeff-bezos-reportedly-halted-amid-ceo-andy-jassys-cost-cutting-drive">Amazon&#8217;s Secret Fertility Tracker Project Launched Under Jeff Bezos Reportedly Halted Amid CEO Andy Jassy&#8217;s Cost-Cutting Drive</a>
Hims &amp; Hers Health shares moved lower on the news. The company&#8217;s strategy involves bringing customers convenient, transparent and affordable access to care. 
In the third quarter, Hims &amp; Hers subscribers jumped 44% year-over-year to 2 million. The company&#8217;s revenue was up 77% year-over-year to $401.6 million, and Hims &amp; Hers raised its full-year outlook to $1.46 billion to $1.465 billion.
&#8220;Our model is rapidly gaining scale, driving accelerating top line growth, improving profitability and strong cash flow. We are seeing this strength across our business,&#8221; CFO Yemi Okupe said in the earnings release.
HIMS Price Action: <a href="http://benzinga.com/quote/HIMS">Hims &amp; Hers Health shares</a> were down 13.8% at $23.77 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Pixabay.

AMZN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Stock Is Tumbling Thursday: What's Going On?

International Flavors &amp; Fragrances, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) shares are trading lower on Thursday. The company launched TEXSTAR, which is an enzymatic solution that enhances the texture of dairy and plant-based fermented products by building<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41964577/iff-launches-texstar-pioneering-enzyme-set-to-transform-fresh-fermented-food-textures" rel="noreferrer noopener"> viscosity without added stabilizers</a>.
TEXSTAR allows manufacturers to achieve distinctive textures with simple, consumer-friendly ingredients, while improving supply chain resilience and reducing Scope 3 emissions associated with texturants.
Marianne Toftdal, global product line manager, Dairy Enzymes, IFF, said, &#8220;With nearly two-thirds of U.K. consumers scrutinizing yogurt ingredients as closely as other foods, TEXSTAR&nbsp;allows the creation of delicious, fresh fermented products with creamy, velvety textures that consumers love, using familiar and consumer-accepted ingredients.&#8221;&nbsp;
This month, International Flavors reported a third-quarter adjusted EPS of $1.04, missing the $1.08 estimate, while sales reached $2.92 billion, surpassing <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41758164/iff-reports-third-quarter-2024-results" rel="noreferrer noopener">the $2.83 billion expectation</a>.
Investors can gain exposure to the stock via&nbsp;iShares Emergent Food and AgTech Multisector ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVEG#NASDAQ">IVEG</a>) and Investment Managers Series Trust III FPA Global Equity ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FPAG#BATS">FPAG</a>).
Price Action: IFF shares are down 1.71% at $88.31 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41852733/fragrance-maker-iff-positioned-for-growth-with-revitalized-rd-and-attractive-valuation-analyst" target="_blank" rel="noreferrer noopener">Fragrance Maker IFF Positioned For Growth With Revitalized R&amp;D And Attractive Valuation: Analyst</a></li>
</ul>

Equities

Northern Lights Fund Trust III FPA Global Equity ETF

FPAG

IVEG

IFF's New TEXSTAR Solution Enhances Texture, Cuts Emissions In Dairy & Plant-Based Foods

Wells Fargo &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) shares are up 13% to $73 since the beginning of November. The stock has seen marked strength following Donald Trump's <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">presidential election win</a>, as investors anticipate that his administration's economic policies could create a favorable climate for major banks. 
Trump&#8217;s tax agenda, which includes potential expansions to the 2017 Tax Cuts and Jobs Act, could lower corporate tax rates further, directly boosting Wells Fargo's earnings. 
Given Wells Fargo's large domestic footprint, the bank stands to benefit substantially from reduced tax burdens, which would improve net income and possibly free up additional funds for shareholder returns through dividends or buybacks.
Read Also: <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a>
What To Know: Trump's stance on regulatory reform is another factor likely driving optimism for Wells Fargo. Under his previous administration, Trump aimed to ease financial industry regulations, including parts of the Dodd-Frank Act, which could lead to a similar approach this time. This deregulation could be advantageous for Wells Fargo as it looks to recover from recent operational and compliance challenges. 
Eased oversight and reduced compliance costs would allow Wells Fargo to focus on core banking activities like consumer lending, small business support and expanding its mortgage portfolio, without the same intensity of regulatory constraints that have limited its growth in recent years.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41971830/producer-inflation-rises-more-than-expected-in-october-should-traders-rethink-interest-rate-cut-path">Producer Inflation Rises More Than Expected In October: Should Traders Rethink Interest Rate Cut Path?</a>
What Else: In addition, Trump's economic policies may create inflationary pressures, especially with proposed spending increases and high tariffs on imported goods. This could prompt the Federal Reserve to keep interest rates elevated, an outcome that would positively impact Wells Fargo's profitability. 
As a bank with a large base of consumer and business loans, Wells Fargo benefits from higher net interest margins when rates are elevated, as it can charge more for lending while controlling deposit costs.
Overall, the combination of potential tax savings, regulatory relief and a higher-rate environment under Trump's policies creates an optimistic outlook for Wells Fargo.
Read Also: <a href="https://www.benzinga.com/news/buybacks/24/11/41971497/tapestry-and-capri-call-off-8-5b-deal-amid-legal-hurdles">Tapestry And Capri Call Off $8.5B Deal Amid Legal Hurdles</a>
<h2 class="wp-block-heading">How To Buy WFC Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Wells Fargo&#8217;s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

What's Going On With Wells Fargo (WFC) Shares

Scotiabank analyst Konark Gupta maintains CAE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CAE#TSX">CAE</a>) with a Sector Perform and raises the price target from C$30 to C$32.5.

Scotiabank Maintains Sector Perform on CAE, Raises Price Target to C$32.5

Hedge Funds

General

Amended 13G Shows Tilman Fertitta Increased Stake In Wynn Resorts From 6.22% To 9.9%

Talis Biomedical (TLIS) has released an update to notify the public and investors about its officers. Talis Biomedical Corporation, following its s...

Talis Biomedical Ends Role of President Amid Reorganization

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Talis Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlis-stock-quote/">TLIS</a>) just reported results for the fourth quarter of 2023.<ul><li>Talis Biomedical reported earnings per share of -$7.39.</li><li>The company reported revenue of $195,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/tlis-stock-earnings-talis-biomedical-for-q4-of-2023/">TLIS Stock Earnings: Talis Biomedical Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TLIS Stock Earnings: Talis Biomedical Reported Results for Q4 2023

The latest update is out from Talis Biomedical (TLIS). Talis Biomedical Corporation has struck a retention deal with Interim CFO Rebecca Markovich,...

Talis Biomedical Secures Interim CFO Amidst Corporate Changes

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Talis Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlis-stock-quote/">TLIS</a>) just reported results for the first quarter of 2024.<ul><li>Talis Biomedical reported earnings per share of -$7.15.</li><li>The company reported revenue of $73,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/tlis-stock-earnings-talis-biomedical-for-q1-of-2024/">TLIS Stock Earnings: Talis Biomedical Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TLIS Stock Earnings: Talis Biomedical Reported Results for Q1 2024

Tracking David Einhorn's Greenlight Capital Portfolio - Q1 2024 Update

Talis Biomedical (TLIS) has shared an update. Talis Biomedical Corporation is undergoing significant board restructuring, which includes the resign...

Talis Biomedical Announces Board Shake-Up Amid Financial Struggles

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!



Earnings reports, an acquisition deal and more are behind today&rsquo;s biggest stock market movements.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Zhongchao (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcmd-stock-quote/">ZCMD</a>) stock is rocketing 78% higher alongside heavy pre-market trading.</li>



<li>G1 Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gthx-stock-quote/">GTHX</a>) shares are soaring more than 65% on <a href="https://finance.yahoo.com/news/pharmacosmos-group-acquire-g1-therapeutics-102900391.html">an acquisition deal</a>.</li>



<li>Richtech Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rr-stock-quote/">RR</a>) stock is surging over 48% with strong early morning trading.</li>



<li>AlphaVest Acquisition Corp &ndash; Right (NASDAQ:<a href="https://investorplace.com/stock-quotes/atmvr-stock-quote/">ATMVR</a>) shares are gaining more than 46% this morning.</li>



<li>Inogen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ingn-stock-quote/">INGN</a>) stock is increasing over 31% with its <a href="https://www.nasdaq.com/press-release/inogen-announces-second-quarter-2024-financial-results-2024-08-06">Q2 earnings report</a>.</li>



<li>Upstart (NASDAQ:<a href="https://investorplace.com/stock-quotes/upst-stock-quote/">UPST</a>) shares are rising more than 25% after <a href="https://finance.yahoo.com/news/upstart-holdings-inc-upst-reports-221010260.html">reporting a Q2 revenue beat</a>.</li>



<li>Lumen Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/lumn-stock-quote/">LUMN</a>) stock is heading over 24% higher <a href="https://www.fool.com/earnings/call-transcripts/2024/08/06/lumen-technologies-lumn-q2-2024-earnings-call-tran/">with its latest earnings</a>.</li>



<li>Veracyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcyt-stock-quote/">VCYT</a>) shares are climbing close to 22% after <a href="https://www.nasdaq.com/press-release/veracyte-announces-second-quarter-2024-financial-results-2024-08-06">announcing its Q2 results</a>.</li>



<li>Direxion Shares ETF Trust Direxion Daily Electric and Autonomous Vehicles Bull 2X Shares (NYSEARCA:<a href="https://investorplace.com/stock-quotes/evav-stock-quote/">EVAV</a>) are jumping more than 19% this morning.</li>



<li>Shopify (NYSE:<a href="https://investorplace.com/stock-quotes/shop-stock-quote/">SHOP</a>) stock is up 18% on <a href="https://za.investing.com/news/stock-market-news/shopify-stock-soars-on-solid-q2-report-issues-q3-guidance-432SI-3275444">solid Q2 earnings results</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Scorpius (NYSEMKT:<a href="https://investorplace.com/stock-quotes/scpx-stock-quote/">SCPX</a>) shares are crashing over 79% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318500722&amp;type=PDF&amp;symbol=SCPX&amp;cdn=70e2821112bdd2f31adb78fe13cd4e38&amp;companyName=Scorpius+Holdings+Inc.&amp;formType=FWP&amp;formDescription=Filing+under+Securities+Act+Rules+163%2F433+of+free+writing+prospectuses&amp;dateFiled=2024-08-07">proposed public offering</a>.</li>



<li>Talis Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlis-stock-quote/">TLIS</a>) stock is plummeting more than 47% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318499549&amp;type=PDF&amp;symbol=TLIS&amp;cdn=2a3bd0b3e041ab6a71139ad061fc0a12&amp;companyName=Talis+Biomedical+Corporation&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-08-06">on restructuring updates</a>.</li>



<li>DZS (NASDAQ:<a href="https://investorplace.com/stock-quotes/dzsi-stock-quote/">DZSI</a>) shares are diving over 45% as it <a href="https://www.nasdaq.com/press-release/dzs-receives-expected-delisting-notice-nasdaq-2024-08-06">prepares for a delisting notice</a>.</li>



<li>Stem (NYSE:<a href="https://investorplace.com/stock-quotes/stem-stock-quote/">STEM</a>) stock is tumbling 38% <a href="https://finance.yahoo.com/news/stem-inc-stem-reports-q2-221513320.html">on Q2 misses</a>.</li>



<li>Nevro (NYSE:<a href="https://investorplace.com/stock-quotes/nvro-stock-quote/">NVRO</a>) shares are taking a more than 37% beating after <a href="https://www.marketwatch.com/story/nevro-shares-fall-21-cuts-2024-revenue-outlook-75cf8aa9?mod=newsviewer_click">cutting its revenue outlook</a>.</li>



<li>Emergent BioSolutions (NYSE:<a href="https://investorplace.com/stock-quotes/ebs-stock-quote/">EBS</a>) stock is sliding over 35% <a href="https://www.stocktitan.net/news/EBS/emergent-bio-solutions-reports-second-quarter-2024-financial-h8fhmjurwquo.html">alongside its Q2 results</a>.</li>



<li>VBI Vaccines (NASDAQ:<a href="https://investorplace.com/stock-quotes/vbiv-stock-quote/">VBIV</a>) shares are dropping more than 34% <a href="https://investorplace.com/2024/08/why-is-vbi-vaccines-vbiv-stock-up-62-today/">after a rally yesterday</a>.</li>



<li>Expion360 (NASDAQ:<a href="https://investorplace.com/stock-quotes/xpon-stock-quote/">XPON</a>) stock is decreasing over 28% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318500633&amp;type=PDF&amp;symbol=XPON&amp;cdn=cc4a67ceca06cec716b8eaa852fb2069&amp;companyName=Expion360+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-08-06">with a public offering</a>.</li>



<li>Evotec (NASDAQ:<a href="https://investorplace.com/stock-quotes/evo-stock-quote/">EVO</a>) shares are falling more than 22% <a href="https://www.investing.com/news/stock-market-news/evotec-shares-crash-36-on-profit-warning-3558654">on a profit warning</a>.</li>



<li>CryoPort (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyrx-stock-quote/">CYRX</a>) stock closes out our pre-market stock movers down over 20% after <a href="https://finance.yahoo.com/news/cryoport-inc-cyrx-reports-q2-230011376.html">missing Q2 estimates</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-aug-7th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Talis Biomedical&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tlis-stock-quote/">TLIS</a>) stock is falling on Wednesday after the company provided investors with an <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318499549&amp;type=PDF&amp;symbol=TLIS&amp;cdn=2a3bd0b3e041ab6a71139ad061fc0a12&amp;companyName=Talis+Biomedical+Corporation&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-08-06">update on its restructuring plans</a>.



Talis Biomedical has brought on two new board members in Patricia Ferrari and John Young, Jr. These two have also elected to serve on a special committee focused on the restructuring of the company.



Talis Biomedical notes that this special committee will focus on a few troublesome matters for the company. That includes ongoing securities class action litigation, determining if the company should file for Chapter 11 bankruptcy and settling any claims made against current or former company leaders in a potential bankruptcy filing.



Talis Biomedical notes that it specifically brought in Ferrari and Young as board members due to their deep experience in bankruptcy and liquidation proceedings. At the same time that they join the board, Heinrich Dreismann has voluntarily resigned from it.



<h2>What This Means for TLIS Stock</h2>



Considering the focus on bankruptcy talk today, it makes sense that investors are spooked. A bankruptcy and liquidation would spell the end of the company and TLIS stock.



With this news comes some 18,000 shares of TLIS stock changing hands. This may not seem like much but it&rsquo;s more than double the company&rsquo;s daily average trading volume.



TLIS stock is down 51.5% this morning.



Investors will want to keep reading for even more of the most recent stock market stories on Wednesday!



We have all of the hottest stock market available today! That includes what&rsquo;s happening with shares of Scorpius&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/scpx-stock-quote/">SCPX</a>) stock, G1 Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/gthx-stock-quote/">GTHX</a>) stock and Zhongchao&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/zcmd-stock-quote/">ZCMD</a>) stock today. All of this info is ready at the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/08/why-is-scorpius-scpx-stock-down-79-today/">Why Is Scorpius (SCPX) Stock Down 79% Today?</a></li>



<li><a href="https://investorplace.com/2024/08/why-is-g1-therapeutics-gthx-stock-up-66-today/">Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?</a></li>



<li><a href="https://investorplace.com/2024/08/why-is-zhongchao-zcmd-stock-up-52-today/">Why Is Zhongchao (ZCMD) Stock Up 52% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-talis-biomedical-tlis-stock-down-52-today/">Why Is Talis Biomedical (TLIS) Stock Down 52% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Talis Biomedical (TLIS) Stock Down 52% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Talis Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlis-stock-quote/">TLIS</a>) just reported results for the second quarter of 2024.<ul><li>Talis Biomedical reported earnings per share of -$4.86.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/tlis-stock-earnings-talis-biomedical-for-q2-of-2024/">TLIS Stock Earnings: Talis Biomedical Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TLIS Stock Earnings: Talis Biomedical Reported Results for Q2 2024

ALIT

ATMVR

BHFAL

BHFAM

BHFAN

BHFAO

BHFAP

CEIX

CYRX

DZSI

EVAV

FCNCA

FCNCB

FCNCO

FCNCP

GLRE

GPOR

GRBK

GTHX

INGN

LIVN

LUMN

NPWR

NVRO

NYCB

SCPX

SHOP

STEM

TCKRF

TECK

TLIS

UPST

VBIV

VCYT

WFRD

WFTUF

XPON

ZCMD

Legal

Press Releases

TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis Biomedical Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Short Sellers

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Talis, TaskUs, and RTR on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Talis Biomedical

Vendite allo scoperto

Talis Biomedical (OTC:TLIS) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO